---------- CBD ----------

22 Phase I Selections from the 10.1 Solicitation

(In Topic Number Order)
Luna Innovations Incorporated
1 Riverside Circle Suite 400
Roanoke, VA 24016
Phone:
PI:
Topic#:
(540) 558-1665
Ruya Ozer
CBD10-101      Awarded: 5/24/2010
Title:Low/No Power Detector for Organophosphate Nerve Agents
Abstract:Organophosphate (OP) nerve agents are the most dangerous chemical warfare agents and therefore pose a significant threat. Rapid and exact identification of the OP agent involved in any hazardous material incident could significantly facilitate the administration of the most effective therapeutic and allow for appropriate measures of protection and decontamination, thereby increasing survival of the warfighter. Luna is proposing to develop a novel no-power colorimetric paper-based sensor that can selectively and sensitively differentiate organophosphate agents (OP). The proposed colorimetric OP sensor (COPS) will be inexpensive, low-volume, portable, disposable, resistant to harsh conditions (high and low temperature), long self-life, and easy-to-use with instantaneous response. In phase I, Luna will develop science behind the recognition elements needed in the detector for capability to differentiate between four OPs in the presence of interferents and from a variety of sources. In Phase II, Luna will develop a sensor capable of distinguishing between four OP agents and three simulants. Luna’s detection technology can also be tailored to other chemical and biological agents of interests.

Lynntech, Inc.
7610 Eastmark Drive
College Station, TX 77840
Phone:
PI:
Topic#:
(979) 693-0017
Waheguru P. Singh
CBD10-101      Awarded: 5/24/2010
Title:No Power Detection and Identification of Nerve Agents
Abstract:Rapid identification of asymmetric warfare modes, including unconventional chemical agents based attacks, is vital to the protection of U.S. armed forces personnel. Existing detection methods use bulky and expensive laboratory equipment to analytically determine the identity and concentration of chemical threats, negating their battlefield use. Colorimetric indicators such as the currently deployed M8 and M9 detection papers are the fastest, cheapest, lightest and easiest type of detector to use; however, these cannot detect vapor form chemical agents, and are highly susceptible to false positives from bug spray, smoke, gasoline and strong bleach. Lynntech proposes development of a passive colorimetric sensor array platform, capable of detecting and identifying a variety of organophosphate based nerve agents. The sensor array will consist of a combination of different nanoparticles based chemistries and color changing dyes. The nanoparticles will be attached permanently to the polymer support that will react with the chemical agent. The reaction products will induce a visible color change to the imbedded dye molecules. The sensor array will operate on a field rugged support to identity levels of chemical threat molecules. The sensors will be sensitive, rugged, reagentless and low cost and will meet the specifications outlined in the solicitation.

LNK Chemsolutions, LLC
4701 Innovation Drive
Lincoln, NE 68521
Phone:
PI:
Topic#:
(630) 854-8173
Luis Nunez
CBD10-102      Awarded: 5/17/2010
Title:Improved Formulations to Enhance Bio-availability for Antisense Therapeutics
Abstract:In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.

Physical Optics Corporation
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
Phone:
PI:
Topic#:
(310) 320-3088
Gregory Zeltser
CBD10-102      Awarded: 5/17/2010
Title:Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device
Abstract:To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to develop a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses in-house developed mature components. POC’s innovations in the nanocarrier (NC) construct and in the design of the inhaler, which is capable of delivering a single dose from the MATEN during one deep and slow inspiration, will enhance the bioavailability for antisense therapeutics that is necessary for the prophylaxes and early treatment of warfighters against emerging bio-warfare threats. As a result, this technology offers a formulation that is stable at ambient temperature, minimizes the potential for introduction of immunogenic materials and the bulk and complexity of dispensing, and which directly addresses the requirements of the Transformational Medical Technologies Initiative (TMTI) program. In Phase I, POC will demonstrate the feasibility of the MATEN by demonstrating product stability and establishing enhanced bioavailability in an animal model. In Phase II, POC will optimize candidate formulation for maximum bioavailability and conduct initial pharmacokinetic and pharmacodynamic studies in an animal model.

CFD Research Corporation
215 Wynn Dr., 5th Floor
Huntsville, AL 35805
Phone:
PI:
Topic#:
(256) 327-0665
Balabhaskar Prabhakarpandian
CBD10-103      Awarded: 5/17/2010
Title:A Novel Microfludic Device for Drug Toxicity Studies
Abstract:Current drug discovery and development programs are severely limited by the expensive animal trials and oversimplified in vitro models. Results obtained from the in vitro models are not predictive of in vivo toxicity owing to significant difference in testing from the in vivo physiological conditions. In this context, we propose to develop and demonstrate a novel microfluidic device for quantitative prediction of the toxicity of the drug agent. This device while accelerating the drug screening development process will also reduce animal trials significantly. Our device accurately reproduces the physiological conditions (morphology, flow and cellular make-up) comprising of the respective cells from the targeted organ of interest. Phase I effort will focus on proof of concept studies using liver cells (hepatocytes) as model for toxicity analysis. In Phase II, the device will be extended to include cells from other targeted organs of interest. Animal experiments will be performed to validate the in vitro model. A high throughput device will be developed by integrating the developed prototype with microwell plates.

Nico Technologies Corp.
401 W. Morgan Road,
Ann Arbor, MI 48108
Phone:
PI:
Topic#:
(734) 945-8131
Kelechi Anyaogu
CBD10-103      Awarded: 5/17/2010
Title:In vitro Models Suitable for High-throughput Screening of Drug Toxicities in Human Tissues
Abstract:The drug R&D cycle is long and very expensive. In many ways, this status quo can no longer be sustained. One of the reasons for such great cost is that the vast majority of drug candidates are screened out at the stages of animal and human trials. More efficient methods of testing of drugs at the stage of ex-vivo studies, which are substantially less expensive than animal and human testing cycles, will lead to improvement of the success rate of preclinical trials, acceleration of drug discovery, reduction of the cost of pharmaceutical development, and better drugs. In this Phase I SBIR project involving a start-up company Nico Technology Corporation (NTCorp) and the University of Michigan, we propose the development of a new type of 3D scaffold that can (1) rectify the problems of existing 3D matrixes and (2) provide the pharmaceutical industry the possibility to develop convenient and reliable protocols for drug assessment in organ replicas, and in particular ex-vivo bone marrow construct.

Physical Optics Corporation
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
Phone:
PI:
Topic#:
(310) 320-3088
Mahsa Rouhanizadeh
CBD10-103      Awarded: 5/17/2010
Title:3D Microfluidic Platform for in vitro Hematopoietic Stem Cell (HSC) Culture
Abstract:To address the Chemical/Bio Defense (CBD) need for in vitro models suitable for high- throughput screening of drug toxicities in human tissues, Physical Optics Corporation (POC) proposes to develop a new three-dimensional (3D) Microfluidic Platform for in-vitro Hematopoietic Stem Cell (HSC) Culture (3D-Mic-Stem). This proposed system is based on a 3D microfluidic design that uses HSCs for assaying high-throughput drug toxicities. The innovation in the 3D microfluidic implementation for stem cell culture and accompanying mitochondrial functionality assay, with the toxicity assay, will enable the system to validate precisely the drug screening process. As a result, this system offers high-throughput screening adaptability, as well as amenability to integration into the system biology architecture. In addition, the human HSCs represent tissue types relevant to toxicological end points, directly addressing the CBD/TMTI program’s requirements. In Phase I, POC will demonstrate the feasibility of 3D-Mic-Stem for drug toxicity screening by designing a proof-of-concept study of the 3D microfluidic culture of HSCs. In Phase II, POC plans to develop initial proof-of-concept studies using drugs with known toxicities and interactions as validation.

Agiltron Corporation
15 Cabot Road
Woburn, MA 01801
Phone:
PI:
Topic#:
(781) 935-1200
Alexander Mazurenko
CBD10-104      Awarded: 8/24/2010
Title:MEMS Lamellar Based Interferometer for the Detection of Toxic Chemicals
Abstract:Leveraging on Agiltron’s industry leading development of optical MEMS devices and the PI’s experience with FTIR spectrometer design, we propose to develop a new class of high performance compact and rugged FTIR spectrometers for LWIR optical range. The design is based on the MEMS lamellar mirror technique. Although this approach is not new, it has not yet been efficiently applied to LWIR, and performance of existing devices is completely inadequate in this range. The Agiltron approach would advance both the resolution and signal-to-noise ratio of MEMS FTIR spectrometers by orders of magnitude. Using the developed lamellar mirror it would be possible to produce a compact instrument similar in function to the Joint Chemical Agent Detector (JCAD). Being based on Infrared Absorption Spectroscopy technique such an instrument would have an advantage of being more sensitive, universal, reconfigurable and less prone to errors and false-positive alarms. The technical approach will be proven in Phase I through the numerical analysis, design, trial manufacturing and testing. A prototype MEMS lamellar spectrometer chip will be produced at the end of Phase I for delivery to the Chemical And Biological Defense Program. Further development and delivery of a complete spectrometer will be proposed for Phase II.

EPIR Technologies Inc
590 Territorial Drive, Suite B
Bolingbrook, IL 60440
Phone:
PI:
Topic#:
(630) 771-0203
Silviu Velicu
CBD10-104      Awarded: 8/3/2010
Title:MEMS Lamellar Based Interferometer for the Detection of Toxic Chemicals
Abstract:In order to satisfy the DOD and commercial needs for the detection and identification of chemical warfare agents, toxic industrial chemicals or biological compounds, we propose a compact, low-cost sensor based on the integration of HgCdTe photodiode detection technology with micro-opto-electromechanical systems (MOEMS) technology, which matches HgCdTe’s sensitivity with an inexpensive microscale MOEMS lamellar grating interferometer (LGI) device. The sensor is operated in stand-off mode and has longer lifetimes than those obtained in conventional solid state sensors based on chemo-sensitive layers. We will fabricate LGI devices operated in short and mid IR wavelength ranges using a modified Silicon-On-Insulator (SOI) process. Prior work has used SOI processing but the deep reactive ion etch (DRIE) used to pattern the thick silicon layer has led to significant roughness on the optical surfaces leading to performance limitations associated with the resulting variability in the optical path length difference. We will use an oxidation and strip process to minimize residual roughness left on the optical surfaces after the DRIE etch step. We have used this processing successfully to remove related sidewall roughness on silicon waveguides and we estimate a final roughness of 0.5 nm in the gratings, suitable for short and mid-IR operation of the fabricated LGIs.

Applied NanoFemto Technologies LLC
181 Stedman St. #2
Lowell, MA 01851
Phone:
PI:
Topic#:
(978) 430-7128
Jarrod Vaillancourt
CBD10-105      Awarded: 6/29/2010
Title:Low noise longwave infrared (8-12µm) focal plane array with high sensitivity for passive hyperspectral standoff detection
Abstract:Longwave infrared (LWIR, 8-12µm) focal plane arrays (FPAs) play an important role in hyperspectral chemical and biological sensing. Existing thermal detectors are unable to meet the high sensitivity and fast response requirements of many hyperspectral chemical and biological sensing applications. Photodetectors and FPAs based on photon excited electron generation process can fulfill the speed and sensitivity requirements. However, they show high noise, and thus need to be cooled down to < 80 K to reduce the noise. The requirement for cryogenic cooling systems adds cost, power consumption and reliability issues, thereby making it unsuitable for standoff sensing and detections. This SBIR proposal aims to develop a new low noise highly sensitive LWIR FPA without the need of cryogenic cooling systems. Such FPA technology would significantly reduce the size weight, and power consumption and especially suitable for standoff hyperspectral chemical and biological sensing and detections. In phase I, the proposed FPA will be evaluated and compared existing FPA technologies. A preliminary FPA design will be generated to meet the requirements of standoff hyperspectral imaging systems. In Phase II, a prototype of the LWIR FPA will be developed and packaged with supporting electronics and optics components to produce a hyperspectral IR camera.

EPIR Technologies Inc
590 Territorial Drive, Suite B
Bolingbrook, IL 60440
Phone:
PI:
Topic#:
(630) 771-0203
Angelo Gilmore
CBD10-105      Awarded: 7/14/2010
Title:Focal Plane Array Technology for Passive Hyperspectral Standoff Detection
Abstract:Chemical imaging sensors require focal plane arrays (FPAs) comprising long wavelength infrared (LWIR) detectors suitable for hyperspectral detection. These detectors require high sensitivity to account for the low photon counts in narrow wavelength bands. The required sensitivity elevates the associated costs, so a need exists for a lower cost LWIR FPA for use with chemical imaging sensors. The technical approach to providing this solution relies on EPIR’s expertise in the molecular beam epitaxy (MBE) growth of HgCdTe on silicon substrates to reduce cost, improve yield and potentially improve performance. The potential performance enhancements include reducing the detector dark current through cost effective material improvements. Phase I of this program will focus on system trades including FPA geometry, spectral response, noise requirements and operating temperature that meet the system requirements while minimizing cost and risk, and maximizing yield. Outputs will include an FPA specifications document as well as single element infrared detector fabrication and characterization. Phase II will focus on infrared detector array manufacture and characterization, and will necessitate a partnership with a system house to integrate the FPA into an integrated detector dewar cryocooler assembly for testing. Phase III will focus on packaging and manufacturing scale-up to further lower costs.

Guild Associates, Inc.
5750 Shier Rings Rd P.O. Box 8013
Dublin, OH 43016
Phone:
PI:
Topic#:
(614) 798-8215
Matt Smiechowski
CBD10-106      Awarded: 8/30/2010
Title:AC Impedance Sensor for Collective Protection Filter Residual Life Indicator
Abstract:Guild Associates, Inc. proposes to develop and evaluate an active electrochemical sensor based residual life indicator (RLI) for adsorptive carbon filters. The sensing system of the RLI will operate by analyzing the electrochemical state of the carbon within the filter and evaluate the remaining adsorptive reactive capacities of the filter. The sensor design will be challenged against an array of common environmental contaminants. Data from the experiments will be used to determine the efficacy of the sensing system, to develop the algorithms for the integrated devices, and to establish design paramanters and miletestones for the development of a prototype device. Succssful completion of the entire project will provide the miliatry with a commercially viable sensor capable of monitoring the status of adsorbent carbon filters.

Morphix Technologies, Inc.
2557 Production Road
Virginia Beach, VA 23454
Phone:
PI:
Topic#:
(757) 431-2260
Ed Locke
CBD10-106      Awarded: 9/29/2010
Title:Residual Life Indicator for Adsorptive and Reactive Single-Pass Filtration Systems
Abstract:In peacetime environments, concerns over improbable encounter with agent threats are supplanted by the need to understand and assess the performance status or residual life (RL) capacity of sorbent-based technologies used in Collective Protection (ColPro) systems. Systems such as the M98 and M48A1 run continuously and therefore sample large volumes of outside air over their lifetime. It is well-known that the performance of the ASZM- TEDA carbon used in these systems is significantly degraded over time as a function of environmental air flow through the sorbent bed. This degradation is primarily due to the presence of several ubiquitous environmental air contaminants including water vapor, sulfur dioxide, and nitrogen oxides. Given the dynamic presence of these environmental contaminants, varying in concentration over time and within and between regions throughout the world, it is critical to assess the RL of filtration media regularly in order to maintain a viable readiness status. These filtration systems use large carbon filters with changeout protocols that are costly and require significant resources, logistics, and system down-time. Additionally, periodic sampling and testing of the filter carbon requires destructive testing, and thus a technology capable of assessing and predicting the RL of these filtration media in real-time, dynamic environments is needed.

Physical Optics Corporation
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
Phone:
PI:
Topic#:
(310) 320-3088
Gary Mikaelian
CBD10-106      Awarded: 6/28/2010
Title:Miniature Residual Life Indicator
Abstract:Impregnated ASZM-TEDA carbon employed as highly adsorptive materials in Collective Protection (ColPro) systems loses the ability to adsorb toxic chemicals because of exposure to temperature, humidity, battlefield contaminants, and other pollutants. To address the Chemical and Biological Defense (CBD) need for a residual life indicator (RLI) capable of probing the degradation in physical adsorption and reactive capacity arising from battlefield contaminants and exposure to the elements, Physical Optics Corporation (POC) proposes developing a new Miniature Residual Life Indicator (MRLIN). This proposed MRLIN is based on impedance spectroscopy measurements performed directly on the filtering system adsorptive material. MRLIN’s innovative algorithm for performing impedance spectroscopy will enable the MRLIN to probe directly the contamination of the active carbon material, with increased accuracy, without the undue complications of readout electronics. This development, as a result, offers a novel system for assessing the residual life of sorbent- based air purification systems that are integrable into ColPro systems. In Phase I, POC will demonstrate the feasibility of MRLIN by assembling and testing a bench-top prototype with three battlefield contaminants representing different poisoning mechanisms. In Phase II, POC plans to develop a field-ready prototype for integration into existing filtration systems and evaluation in relevant conditions.

CFD Research Corporation
215 Wynn Dr., 5th Floor
Huntsville, AL 35805
Phone:
PI:
Topic#:
(256) 327-0666
Ketan Bhatt
CBD10-107      Awarded: 5/10/2010
Title:Microfluidic High-throughput Platform for Determining of Kinetic Constants of Enzyme Variants
Abstract:Molecular biology techniques allow generating combinatorial libraries of large number of enzyme variants. However, there is currently no technology available for screening the enzyme libraries for identifying variants with improved activity for the substrate. We propose to develop a novel, microfluidic, high-throughput platform for determining kinetic constants of enzyme variants and identifying variants with improved affinity for organophosphorus (OP) agents. During Phase I, proof-of-concept will be established by determining the kinetic parameters for the hydrolysis of paraoxon, parathion and diisopropyl fluorophosphate by the catalytic enzyme organophosphorus hydrolase. Integrated on-chip valves will be used for precise metering of reagents. Impedance spectroscopy will be used to monitor reaction progress and completion and ultimately to determine enzyme activity. A preliminary design for the Phase II end-product will be developed for a high-throughput capability. During Phase II, the platform will be further optimized and validated using multiple OP stimulants and for determining enzyme affinity in blood plasma samples. This will be followed by independent third-party testing of the platform with bona fide OP nerve agents. We have assembled an interdisciplinary team of engineers and scientists from CFDRC and Auburn University with expertise in design, modeling, fabrication and experimental characterization of microfluidic systems for a successful development of the proposed platform.

Physical Optics Corporation
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
Phone:
PI:
Topic#:
(310) 320-3088
Gregory Zeltser
CBD10-107      Awarded: 5/17/2010
Title:Microfluidic Dielectrophoretic Screening System
Abstract:To address the U.S. Army/DTRA’s CBD program need for a robust screening process for use with large panels of enzymes to identify variants with higher affinity for organophosphorus (OP) substrates, Physical Optics Corporation (POC) proposes to develop a Microfluidic Dielectrophoretic Screening (MDS) system. This proposed system is based on the new design of a microfluidic mixer, enzymatic reactor, and readout unit that uses in-house developed mature components. The innovations in the MDS system will enable the completion of enzyme kinetic measurements in 15 minutes. Also, the MDS system requires nanogram quantities of an enzyme; and the microfluidic chip is self-contained, reusable, and sufficiently robust to withstand routine cleaning with highly basic and alcoholic solutions. As a result, this technology will provide the DoD with an improved capability to develop novel scavengers of OP nerve agents. In Phase I, POC will demonstrate the feasibility of the MDS system by developing a robust and high-throughput prototype capable of identifying enzyme variants with reduced KM values for OP compounds. In Phase II, POC plans to further develop, refine, and validate the MDS system, using nerve agent simulants followed by validation with OP nerve agents, at a testing facility approved for using these materials.

Agave BioSystems, Inc.
P.O. Box 100
Ithaca, NY 14850
Phone:
PI:
Topic#:
(607) 272-0002
Julien Fey
CBD10-108      Awarded: 5/21/2010
Title:A High-Throughput Blood Esterase Panel Assay
Abstract:Organophosphorus chemical warfare nerve agents (OP-CWA) are attractive to terrorist groups and rogue states as an inexpensive and accessible technology for chemical warfare. OP-CWA and organophosphate pesticides cause severe neurological symptoms and death by inhibiting the enzyme acetylcholinesterase (AChE); the resulting excess acetylcholine accumulates and overstimulates the human or animal body. Other esterases and organophosphatases in the blood either bind (butyrylcholinesterase, BChE) or catalytically degrade (paraoxonase, PON1) OP-CWA. Therefore, it is critically important to be able to quickly monitor the human blood complement of OP-CWA enzymes to assess both susceptibility and current condition. For military and civilian clinical use, a high-throughput, minimally invasive assay system is needed to quickly and accurately screen large numbers of soldiers/agricultural workers/first responders for OP-CWA or OP-pesticide exposure. The currently available WRAIR assay is high-throughput, uses a minimal amount of whole blood, and is sensitive and accurate for AChE and BChE levels. An assay that additionally measures PON1 and albumin esterase activities relevant to OP degradation and/or binding is greatly needed to more fully assess OP-CWA or -pesticide susceptibility for individuals at risk.

Lynntech, Inc.
7610 Eastmark Drive
College Station, TX 77840
Phone:
PI:
Topic#:
(979) 693-0017
Jinseong Kim
CBD10-108      Awarded: 6/15/2010
Title:Electrochemical Screening of Multiple Enzymes Relevant to Organophosphate Poisioning
Abstract:Organophosphorus (OP) compounds have been extensively used as pesticides and chemical warfare agents . Potential OPs exposure exists both on the battlefield and in the civilian sector. OPs exposure inhibits enzyme activity, allowing excess acetylcholine to accumulate. Screening of multiple enzymes is highly desirable because it may provide a comprehensive description of the warrior’s capacity for low level OP exposure. Current screening use the colorimetric Ellman assay based on the hydrolysis of acetylthiocholine. Some alternative approaches, such as radiometric assay, immunoassay, fluorescence, chemiluminescence, or mass spectroscopy, have been reported for sensitive detection of enzyme activities. However, these assays are tedious and/or time-consuming, require expensive and sophisticated instruments, or are limited to a single enzyme. Thus, development of high- throughput, minimally invasive blood protocol to measure the human profile of enzymes affected by organophosphate chemical warfare agents is needed. It will provide the army and general public health clinics the capability of screening and confirming exposure of soldiers/agricultural workers/first responders to chemical warfare agents/pesticides/or other such toxic chemicals. Lynntech proposes to develop a simple, rapid, sensitive, hand-held field deployable biomonitoring device based on electrochemical detection principles. During Phase I, the proof-of-concept will be demonstrated. During Phase II, prototype assays will be developed.

Impel NeuroPharma
867 SW Shoremont Ave
Normandy Park, WA 98166
Phone:
PI:
Topic#:
(206) 200-2800
Rodney J.Y. Ho
CBD10-109      Awarded: 7/12/2010
Title:Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents
Abstract:This program plans to develop a drug delivery system that provides maximum oxime drug exposure and improve cholinesterase reactivation in the brain and tissues of central nervous system (CNS) of a warfighter after exposure to organophosphate (OP) poisoning. The greatest need for improvement in cholinesterase reactivation is the ability to deliver charged cholinesterase reactivators to the CNS that do not readily cross the blood-brain barier (BBB). The current combination drug therapy requires infusion of high doses of drugs and is not well-suited for battlefield administration. Impel NeuroPharma has developed a novel non-invasive intranasal drug delivery technology that will bypass the BBB thereby allowing a maximum drug exposure and cholinesterase reactivation. Instead of depositing drugs to the lower nasal cavity (achieved with traditional nasal delivery devices), this technology deposits drugs into the upper 1/3 of the nasal cavity and provides direct access to the brain and CNS (via the olfactory cells), thereby improving the efficiency of CNS delivery. This proposed program will formulate oximes for delivery into the brain and CNS using this device and evaluating it in appropriate animal models. We envision that this product will be used in theater to counteract the effects of OP poisoning.

Redondo Optics, Inc.
811 N. Catalina Avenue, Suite 1100
Redondo Beach, CA 90277
Phone:
PI:
Topic#:
(310) 292-7673
Edgar A. Mendoza
CBD10-110      Awarded: 5/24/2010
Title:Next Generation Integrated Electrophoretic Nanofluidic Biochip Sensor Platform for the THz Spectroscopic Finger Printing of Biological Species and Age
Abstract:Redondo Optics Inc. (ROI), a world leader in engineering and manufacturing of leading- edge nano-materials, optical sensors, fiber and integrated optics, and advanced photonics instrumentation proposes to develop and demonstrate an integrated electrophoretic nanofluidic biochip sensor platform for the accurate, reliable, and fast-throughput “label- less” THz spectroscopy finger printing of biological species and agents. Nanotechnology is emerging as the critical field for the next generation evolution of analytical biochip technology that will provide significant breakthroughs for affecting biomedicine. Miniaturization to the nanometer scale enables the probing of fundamental biological processes such as the epigenetic and genetic control factors of single molecules. Specifically, nanofluidic biochips can be use for the direct visualization of single DNA molecules. In Phase I, Redondo Optics will demonstrate an integrated THz nanofluidic biochip sensor platform that will enable the label-free fluid analysis of genetic material. The primary goal of this project is to validate and establish the use of the integrated THz nanofluidic biochip sensor platform as an analytical tool to allow the direct detection, identification, and classification of nucleic acids such as DNA and RNA in their native aqueous environment without the need of complex sample preparation procedures. In Phase II of this program, ROI will focus on the engineering development of a manufacturable optical nanolithography technology to enable the cost affordable production of disposable nanofluidic biochip arrays.

VIBRATESS
2020 Avon CT., Suite 43
Charlottesville, VA 22902
Phone:
PI:
Topic#:
(434) 296-2400
Oguz Dogan
CBD10-110      Awarded: 9/8/2012
Title:DEVELOPMENT OF A BIOSENSOR NANOFLUIDIC PLATFORM FOR INTEGRATION WITH TERAHERTZ SPECTROSCOPIC SYSTEM
Abstract:The goal of this SBIR project is to develop and demonstrate an electrokinetically driven nanofluidic sensor device of the physical size and shape that will allow integration with a THz spectroscopic instrument. The substrate and channel surfaces within t

VIBRATESS
2020 Avon CT., Suite 43
Charlottesville, VA 22902
Phone:
PI:
Topic#:
(434) 296-2400
Oguz Dogan
CBD10-110      Awarded: 5/24/2010
Title:DEVELOPMENT OF A BIOSENSOR NANOFLUIDIC PLATFORM FOR INTEGRATION WITH TERAHERTZ SPECTROSCOPIC SYSTEM
Abstract:The goal of this SBIR project is to develop and demonstrate an electrokinetically driven nanofluidic sensor device of the physical size and shape that will allow integration with a THz spectroscopic instrument. The substrate and channel surfaces within the device will be appropriate for the acquisition of THz-frequency spectroscopic features from bio-molecules (e.g., DNA, RNA, proteins) in solutions and for their effective label-free detection and identification. Flow within the device will be controlled, and interactions required for capture or processing of relevant biomolecules for fingerprinting will be incorporated into the same device. The Phase I effort of this project is the development of a conceptual design of a proposed nanofluidic sensor package to demonstrate the feasibility of a biosensor system for biological targets detection. The specification of the requirements for a spectroscopic instrument for the acquisition of THz-frequency spectroscopic features from biomolecules will be created. Preliminary experimental characterization of fluidic channels electrokinetic characteristics and optical efficiency will be conducted. In the Phase II a completely functioning nanofluidic sensor platform will be implemented and combined with THz spectroscopic system. The proposed project will be conducted by Vibratess LLc in close collaboration with Pettit Applied Technologies, and with Lichtenberger Consultanting.